Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-CN: Orforglipron vs placebo for weight management in Chinese adults with obesity or overweight and comorbidities
CTR20263226Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in obesity, Overweight, sponsored by Eli Lilly and Company. Started Aug 2026; status: active.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20263226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263226.